parenteral News
-
Mechatronics for life!
Thanks to precise, reliable Mechatronics solutions, we help our Pharma and Medtech customers globally in improving the life of patients. We strive to enhance convenience and safety of parenteral drug delivery and compliance to therapeutic regimen with innovative, reliable and cost effective wearable medical devices and customized solutions that feature Mechatronics at their core. We are ...
By Sonceboz SA
-
CD Formulation Announces Ability to Develop Liquid Dosage Forms
CD Formulation is known as a CRO service provider for custom pharmaceutical formulation projects. In a recent statement, the company announced its ability in liquid dosage forms development for customers worldwide who are looking for liquid dosage forms solutions for their drug development projects. There are different types of dosage forms, such as solid dosage form, liquid dosage form, ...
-
CD Formulation Announces Ability to Develop Liquid Dosage Forms
CD Formulation is known as a CRO service provider for custom pharmaceutical formulation projects. In a recent statement, the company announced its ability in liquid dosage forms development for customers worldwide who are looking for liquid dosage forms solutions for their drug development projects. There are different types of dosage forms, such as solid dosage form, liquid dosage form, ...
-
Minaris Regenerative Medicine Strengthens Global and Regional Leadership
Minaris Regenerative Medicine is pleased to announce new appointments to strengthen its global and regional leadership. Minaris Regenerative Medicine, having facilities in the U.S., Germany, and Japan, will shift to a model of regional operational leadership on October 1, 2021. Under the new model, its three regional Chief Operating Officers (COOs) will collaborate on a Global Functional team to ...
-
CD Formulation Enables Customized Synthesis Service for Osmotic Pressure Regulators for Drug Development
Normal cell function requires the maintenance of osmotic pressure. Therefore, in drug manufacturing, osmotic pressure regulators should be added to the formulation to avoid tissue damage. The US-based CRO company CD Formulation recently announced its ability to synthesize osmotic pressure regulators to suit the needs of different drug projects. These osmotic pressure regulators will help ...
-
CD Formulation Stresses the Importance of Increased Bioavailability Excipients in Drug Formulation
Specializing in drug formulation, the highly specialized CRO service provider CD Formulation has accumulated abundant experience in the custom synthesis of increased bioavailability excipients. To meet the requirements of different drug research projects, excipients can be tailor-made in varied specifications and volumes. Recently, adding increased bioavailability excipients in drug formulations ...
-
CD Formulation Launches Tailored Solutions for Increased Bioavailability Excipients for Drug Development
In a recent statement, the York-based CRO company CD Formulation announces the launch of tailored solutions for increased bioavailability excipients, which aims to tackle the issue of poor bioavailability, a long-lasting challenge in drug development. Many drug candidates unfortunately stopped their way ahead from the discovery pipeline just simply because they are poorly water-soluble, which ...
-
Enalare Files Additional Patent Application for Lead Compound ENA-001 - Enhancing Potential Global Exclusivity Through 2042
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has filed a Provisional Patent Application with the United States Patent and Trademark Office directed to parenteral formulations of ENA-001 and related compounds. The patent application encompasses the ...
-
Creative Diagnostics Launches Staphylococcal Enterotoxin Antigens
As a global leading supplier of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently launches a range of natural and recombinant staphylococcal enterotoxin antigens that are well validated in double-antibody sandwich enzyme-linked immunosorbent assay (ELISA). The newly introduced antigens consist of five of the most common staphylococcus aureus ...
-
Contaminated IV Solution Points to Need for USP 797 Implementation and Compliance
CNN recently reported that nineteen patients in six Alabama hospitals became infected with the bacterium Serratia marcescens after receiving contaminated intravenous total parenteral nutrition (TPN). Nine of the 19 patients have died. Investigators are working to determine if the infection from the bacterium found inside the IV bags of TPN solution is directly responsible for the patient ...
-
Reorganized Collection of Pharmaceutical Excipients Now Released at CD Formulation
Since its launch, the pharmaceutical excipients provided by CD Formulation have gained significant popularity among customers worldwide. To enhance the search process, CD Formulation has recently reorganized its collection of pharmaceutical excipients and unveiled these changes on its website. With a focus on improving drug delivery systems and dosage forms, the company aims to offer innovative ...
-
What Are D-Glucosamines?
Glucosamine is a natural component of cartilage and is widely used as an over-the-counter nutritional supplement to reduce the pain and cartilage loss of osteoarthritis. Glucosamine is usually taken in combination with chondroitin, which is a glycosaminoglycan that also exists in cartilage.Glucosamine is an amino sugar and an important molecule in the biochemical pathway of glycosylated protein ...
-
PDA Announces the Jette Christensen Early Career Professional Grant in Memory of Past PDA Chair
PDA today announced the establishment of the Jette Christensen Early Career Professional Grant in memory of the Immediate-Past Chair of the PDA Board of Directors, who passed away on October 24 after a long battle with cancer. As a PDA member, Board Member, and PDA Chair, Jette’s dedication to PDA’s mission of advancing pharmaceutical/biopharmaceutical manufacturing science and ...
-
U.S. FDA approves Xarelto to treat venous thromboembolism (VTE) and to prevent VTE in children
Xarelto is the only Factor Xa anticoagulant FDA approved for pediatric patients and offers a flexible weight-based dosing Xarelto is available in both oral tablet and liquid suspension formulations for use in appropriate children less than 18 years of age Convenient liquid formulation advances standard of care for children; alleviates administration challenges found with injectable ...
By Bayer AG
-
Lauren Sciences LLC research team at Ben-Gurion University successfully completes Campbell Foundation 1-year grant to develop V-Smart therapeutic for neuro-HIV
New York, N.Y., October 22, 2013 -- Lauren Sciences LLC, a privately-held biotechnology company furthering development of V-Smart™ therapeutics based upon its novel nanovesicle platform technology, announced today successful completion by its research team at Ben-Gurion University of the first stage of developing a V-Smart™ therapeutic for the treatment of neuro-HIV. The development ...
-
STEMart Launches Microbiology & Sterility Testing Services for Medical Devices
STEMart, a provider of integrated medical device CRO services dedicated to medical device and diagnostic clinical development, introduces comprehensive microbiology and sterility testing for sterile, non-pyrogenic products. STEMart has extensive expertise in microbiology as well as sterility testing and remains dedicated to a full-service experience that supports manufacturers in meeting ...
By STEMart
-
Rivaroxaban (Xarelto) approved in Japan for patients with peripheral artery disease (PAD) after revascularisation
The Ministry of Health, Labor and Welfare in Japan has approved the use of the oral Factor Xa inhibitor rivaroxaban (Xarelto™) (2.5 mg twice daily, used in combination with aspirin 81-100 mg once daily) to treat patients with peripheral artery disease (PAD) after revascularization. The approval is based on data from the Phase III VOYAGER PAD trial. This study demonstrated a positive ...
By Bayer AG
-
New real world study data on reduced risk of adverse kidney outcomes for Xarelto compared to VKA
In the prospective observational XARENO study, after a two year follow up period, Xarelto was associated with a reduced risk of adverse kidney outcomes and all-cause mortality in patients with non-valvular atrial fibrillation (NVAF) and advanced chronic kidney disease (CKD), compared to vitamin K antagonists (VKA) XARENO evaluated the impact of Xarelto in patients with NVAF and CKD, given that ...
By Bayer AG
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you